Skip to main content

ZTALMY

Generic: ganaxolone

Data may be stale·Apr 23, 2026
Manufacturer
Marinus
NDC
81583-100
RxCUI
2604694
Route
ORAL
ICD-10 indication
G40.42

Affordability Check

How much will you actually pay for ZTALMY?

In 30 seconds, see every legitimate way to afford ZTALMY — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About ZTALMY

What is this medication? ZTALMY is a prescription oral suspension used for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, which is frequently abbreviated as CDD. This condition is a rare genetic form of epilepsy that often starts in early infancy and is characterized by difficult-to-control seizures and significant developmental challenges. The medication is specifically indicated for pediatric and adult patients who are two years of age and older.

The active ingredient in this medication is ganaxolone, a neuroactive steroid that acts as a GABA receptor positive modulator. It functions by interacting with specific receptors in the central nervous system to help stabilize brain activity and reduce the frequency of seizures. It is typically taken three times daily with food, and it represents a targeted therapeutic option for individuals living with the complex neurological symptoms of CDD.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How ZTALMY appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

55%

3,029 of 5,499 plans

Most common tier

Tier 5

On 78% of covering formularies

Prior authorization required

98%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)59
18%
Tier 2 (generic)2
1%
Tier 4 (non-preferred brand)11
3%
Tier 5 (specialty)255
78%
Tier 61
0%

Step therapy: 0% of formularies

Quantity limits: 83% of formularies

Coverage breadth: 328 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

Yes——

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.

Rare-disease navigation (specialists, trials, patient communities)

ZTALMY treats a rare condition. For in-depth disease pages on our sister site:

UniteRare.org is our sister site for rare-disease navigation — same editorial team, same accuracy standards.